Campbell & CO Investment Adviser LLC
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1353570
BALTIMORE, MD
Position in PTGX
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$760,731
-$1,078,125 QoQ
Shares Held
6,206
-70.5% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#186
of 341 holders
Holding Since
Jun 2023
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $72,173,828 across 47 Biotechnology names. PTGX ranks #26 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in PTGX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $760,731 | 6,206 | Shares | Sole | 2026-08-03 | |
| 2025-12-31 | $1,838,856 | 21,054 | Shares | Sole | 2026-02-12 | |
| 2025-03-31 | $919,565 | 19,015 | Shares | Sole | 2025-05-14 | |
| 2024-03-31 | $398,163 | 13,763 | Shares | Sole | 2024-05-10 | |
| 2023-09-30 | $943,704 | 56,577 | Shares | Sole | 2023-11-08 | |
| 2023-06-30 | $567,811 | 20,558 | Shares | Sole | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||